Will Pazopanib be reimbursed by medical insurance?

Pazopanib (Pazopanib) The original drug has been approved by the State Food and Drug Administration for marketing in China, and has subsequently entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Bureau, but it is limited to the first-line treatment of patients with advanced renal cell carcinoma and the treatment of advanced renal cell carcinoma who have received cytokine therapy. Patients who do not meet the requirements can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may also be different, but it is relatively cheaper than purchasing it at your own expense. The price of each box of pazopanib may be around RMB 3,000. For specific medical insurance reimbursement information, please consult the local medical insurance bureau or hospital.